Sentiment-Signal
16,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Unternehmen & Branche
| Name | Dianthus Therapeutics, Inc. /DE/ |
|---|---|
| Ticker | DNTH |
| CIK | 0001690585 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,23 Mrd. USD |
| Beta | 0,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 2,036,000 | -162,337,000 | -4.20 | 530,922,000 | 493,401,000 |
| 2025-09-30 | 10-Q | 396,000 | -36,765,000 | -0.97 | 577,445,000 | 546,454,000 |
| 2025-06-30 | 10-Q | 193,000 | -31,629,000 | -0.88 | 326,076,000 | 303,079,000 |
| 2025-03-31 | 10-Q | 1,163,000 | -29,511,000 | -0.82 | 348,580,000 | 328,606,000 |
| 2024-12-31 | 10-K | 6,235,000 | -84,969,000 | -2.55 | 374,008,000 | 352,477,000 |
| 2024-09-30 | 10-Q | 2,172,000 | -25,174,000 | -0.74 | 354,248,000 | 337,898,000 |
| 2024-06-30 | 10-Q | 1,863,000 | -17,607,000 | -0.51 | 368,959,000 | 358,218,000 |
| 2024-03-31 | 10-Q | 874,000 | -13,748,000 | -0.54 | 382,462,000 | 372,687,000 |
| 2023-12-31 | 10-K | 2,826,000 | -43,555,000 | -8.45 | 179,405,000 | 168,870,000 |
| 2023-09-30 | 10-Q | 924,000 | -14,763,000 | -3.78 | 192,462,000 | 178,381,000 |
| 2023-06-30 | 10-Q | -11,140,000 | -12.73 | 78,638,000 | -61,460,000 | |
| 2023-03-31 | 10-Q | -7,089,000 | -8.10 | 83,441,000 | -50,820,000 | |
| 2022-12-31 | 10-K | -28,476,000 | -32.57 | 83,110,000 | -44,368,000 | |
| 2022-12-31 | 10-Q | -76,500,000 | 83,110,000 | -44,368,000 | ||
| 2022-09-30 | 10-Q | 1,173,000 | -7,784,000 | -8.90 | 164,123,000 | -34,754,000 |
| 2022-06-30 | 10-Q | -5,695,000 | -0.29 | 175,121,000 | -27,481,000 | |
| 2022-03-31 | 10-Q | -4,881,000 | -0.39 | 194,385,000 | -22,065,000 | |
| 2021-12-31 | 10-Q | -71,100,000 | 189,934,000 | -17,249,000 | ||
| 2021-12-31 | 10-K | -71,136,000 | -1.29 | 189,934,000 | -17,249,000 | |
| 2021-09-30 | 10-Q | -17,427,000 | -0.30 | 206,236,000 | 189,688,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-09 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -8,224 | 89.84 | -738,844.16 | -54,8% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -59,800 | 83.90 | -5,017,220.00 | -372,1% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -21,825 | 78.86 | -1,721,119.50 | -127,7% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -2,366 | 82.84 | -195,999.44 | -14,5% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -19,469 | 84.57 | -1,646,493.33 | -122,1% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -7,232 | 85.54 | -618,625.28 | -45,9% | |
| 2026-03-31 | Soteropoulos Paula | Director | Open Market Sale | -599 | 80.11 | -47,985.89 | -3,6% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -800 | 81.36 | -65,088.00 | -4,8% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -1,390 | 78.33 | -108,878.70 | -8,1% | |
| 2026-03-31 | Savitz Ryan | Officer, EVP, CFO & CBO | Open Market Sale | -1,485 | 80.25 | -119,171.25 | -8,8% | |
| 2026-03-24 | Soteropoulos Paula | Director | Open Market Sale | -27,594 | 78.05 | -2,153,711.70 | -159,7% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -43,505 | 80.69 | -3,510,418.45 | -260,4% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -200 | 83.38 | -16,676.00 | -1,2% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -300 | 85.53 | -25,659.00 | -1,9% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -3,865 | 82.66 | -319,480.90 | -23,7% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -15,852 | 80.71 | -1,279,414.92 | -94,9% | |
| 2026-03-12 | CARR EDWARD | Officer, CHIEF ACCOUNTING OFFICER | Open Market Sale | -23,465 | 81.75 | -1,918,263.75 | -142,3% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -200 | 83.38 | -16,676.00 | -1,2% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -900 | 85.53 | -76,977.00 | -5,7% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -12,796 | 82.60 | -1,056,949.60 | -78,4% | |
| 2026-03-12 | Garcia Marino | Director, Officer, CEO AND PRESIDENT | Open Market Sale | -65,517 | 81.74 | -5,355,359.58 | -397,2% | |
| 2026-03-12 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -33,830 | 81.48 | -2,756,468.40 | -204,5% | |
| 2025-12-04 | Savitz Ryan | Officer, CFO & CBO | Open Market Sale | -20,000 | 45.18 | -903,600.00 | -67,0% | |
| 2025-11-14 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -109,031 | 38.14 | -4,158,442.34 | -308,4% | |
| 2025-11-13 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -42,765 | 37.04 | -1,584,015.60 | -117,5% | |
| 2025-11-13 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -26,166 | 35.80 | -936,742.80 | -69,5% | |
| 2025-11-13 | Randhawa Simrat | Officer, EVP, Head of R&D | Open Market Sale | -18,576 | 37.72 | -700,686.72 | -52,0% | |
| 2025-09-09 | Savitz Ryan | Officer, CFO & CBO | Open Market Sale | -20,000 | 35.00 | -700,000.00 | -51,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.